Aileron Therpeutics


Aileron Therapeutics is a biopharmaceutical company developing and advancing a revolutionary class of drugs called Stapled Peptides. The company’s proprietary Stapled Peptides platform is a breakthrough approach to creating drugs for highly sought after biological targets using its novel peptide stabilizing technologies. Aileron’s Stapled Peptides have demonstrated their unique ability to penetrate cells throughout the body and modulate intracellular and extracellular protein-protein interactions, critical control points for most human diseases. The ability to target and regulate these control points affords the unique opportunity to exploit potentially thousands of well characterized, yet currently “undruggable” cellular targets with applications in all human diseases. The Aileron technology works by locking peptides into their biologically active shape, mimicking the structures found in nature, and ultimately endows the peptide with unique and beneficial drug-like properties, including efficient cell penetration, high affinity binding to large target protein surfaces, specificity, and excellent stability within the body.

Other investors include: Apple Tree Partners, Excel Venture Management, Novartis Venture Fund, Roche Ventures, and SR One.